Your browser doesn't support javascript.
loading
Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer.
Apolo, Andrea B; Milowsky, Matthew I; Kim, Lauren; Inman, Brant A; Kamat, Ashish M; Steinberg, Gary; Bagheri, Mohammadhadi; Krishnasamy, Venkatesh P; Marko, Jamie; Dinney, Colin P; Bangs, Rick; Sweis, Randy F; Maher, Virginia Ellen; Ibrahim, Amna; Liu, Ke; Werntz, Ryan; Cross, Frank; Beaver, Julia A; Singh, Harpreet; Pazdur, Richard; Blumenthal, Gideon M; Lerner, Seth P; Bajorin, Dean F; Rosenberg, Jonathan E; Agrawal, Sundeep.
Affiliation
  • Apolo AB; National Institutes of Health, Bethesda, Maryland.
  • Milowsky MI; Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill.
  • Kim L; National Institutes of Health, Bethesda, Maryland.
  • Inman BA; Department of Surgery, Duke Cancer Institute, Durham, North Carolina.
  • Kamat AM; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston.
  • Steinberg G; NYU Langone Health, New York, New York.
  • Bagheri M; National Institutes of Health, Bethesda, Maryland.
  • Krishnasamy VP; National Institutes of Health, Bethesda, Maryland.
  • Marko J; National Institutes of Health, Bethesda, Maryland.
  • Dinney CP; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston.
  • Bangs R; National Institutes of Health, Bethesda, Maryland.
  • Sweis RF; University of Chicago Medicine, Chicago, Illinois.
  • Maher VE; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Ibrahim A; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Liu K; Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Werntz R; University of Chicago Medicine, Chicago, Illinois.
  • Cross F; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Beaver JA; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Singh H; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Pazdur R; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland.
  • Blumenthal GM; Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, Maryland.
  • Lerner SP; Department of Urology, Baylor College of Medicine, Houston, Texas.
  • Bajorin DF; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Rosenberg JE; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Agrawal S; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
JAMA Oncol ; 5(12): 1790-1798, 2019 12 01.
Article in En | MEDLINE | ID: mdl-31670753
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell / Clinical Trials as Topic / Cisplatin / Patient Selection Type of study: Guideline Limits: Humans Language: En Journal: JAMA Oncol Year: 2019 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell / Clinical Trials as Topic / Cisplatin / Patient Selection Type of study: Guideline Limits: Humans Language: En Journal: JAMA Oncol Year: 2019 Document type: Article